Last reviewed · How we verify

FTY720 — Competitive Intelligence Brief

FTY720 (FTY720) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sphingosine-1-phosphate receptor modulator; Immunomodulator. Area: Immunology.

marketed Sphingosine-1-phosphate receptor modulator; Immunomodulator Sphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5) Immunology Small molecule Live · refreshed every 30 min

Target snapshot

FTY720 (FTY720) — Novartis Pharmaceuticals.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
FTY720 TARGET FTY720 Novartis Pharmaceuticals marketed Sphingosine-1-phosphate receptor modulator; Immunomodulator Sphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5)
fingolimob (FTY) fingolimob (FTY) University Hospital, Clermont-Ferrand marketed Sphingosine-1-phosphate receptor modulator S1P1 receptor (sphingosine-1-phosphate receptor 1)
Placebo matching fingolimod Placebo matching fingolimod Biogen phase 3 Sphingosine-1-phosphate receptor modulator S1P1, S1P3, S1P4, S1P5 (sphingosine-1-phosphate receptors)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sphingosine-1-phosphate receptor modulator; Immunomodulator class)

  1. Novartis Pharmaceuticals · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). FTY720 — Competitive Intelligence Brief. https://druglandscape.com/ci/fty720. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: